Infectious Disease Molecular Diagnostics Market by Product (PCR-Based Diagnostics, Isothermal Amplification, Next-Generation Sequencing (NGS)); Technology (Polymerase Chain Reaction (PCR), Real-Time PCR, Reverse Transcription PCR (RT-PCR)); Application (Respiratory Infections, Bloodstream Infections, Sexually Transmitted Infections (STIs), Gastrointestinal Infections); End-Use Industry (Hospitals and Diagnostic Laboratories, Point-of-Care Testing) and by Region; Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Infectious Disease Molecular Diagnostics Market was valued at USD 5.7 Billion in 2024-e and will surpass USD 11.6 Billion by 2030; growing at a CAGR of 12.4% during 2025 - 2030.

The Infectious Disease Molecular Diagnostics market is witnessing significant growth due to increasing demand for precise, rapid, and reliable diagnostic tools for infectious diseases. The need for accurate diagnostics has grown alongside the global rise in infectious diseases, including respiratory infections, bloodstream infections, sexually transmitted infections (STIs), and gastrointestinal infections. The market is driven by advancements in molecular diagnostic technologies, including PCR-based diagnostics, next-generation sequencing (NGS), and isothermal amplification, which enable highly sensitive and specific detection of pathogens. These technologies are integral in the early detection and treatment of infections, enabling better patient outcomes and improved infection control.

The shift toward molecular diagnostics represents a significant advancement over traditional diagnostic methods, such as microbiological cultures, which are often time-consuming and less accurate. Molecular diagnostics provide faster results, allowing healthcare providers to deliver timely treatments, reduce the risk of complications, and minimize the spread of infections. As molecular diagnostic technologies continue to evolve, they are becoming more accessible and widely used in various healthcare settings, including hospitals, diagnostic laboratories, and point-of-care testing environments. This trend is expected to continue, further driving the growth of the market as healthcare systems globally seek to improve diagnostic accuracy and efficiency.

PCR-Based Diagnostics Are Largest Segment Owing to Versatility and High Sensitivity

PCR-based diagnostics are the largest segment in the infectious disease molecular diagnostics market, owing to their high sensitivity and ability to detect minute amounts of pathogen DNA or RNA. PCR (Polymerase Chain Reaction) technologies allow for the amplification of genetic material, enabling the detection of a wide range of infectious agents, including bacteria, viruses, and fungi. The versatility of PCR-based diagnostics makes it the go-to solution for detecting a variety of infectious diseases, such as respiratory infections, gastrointestinal infections, and sexually transmitted infections (STIs), among others.

The widespread adoption of PCR in both clinical and research settings is fueled by its ability to provide highly accurate and timely results. PCR-based diagnostics are used to detect infections early, even before symptoms appear, which is crucial for controlling the spread of contagious diseases. Additionally, PCR is widely used in epidemiological surveillance, aiding in the identification of emerging infectious diseases. The demand for PCR-based diagnostics is expected to remain strong as healthcare providers continue to rely on this proven and reliable technology to improve diagnostic capabilities and patient care.

Next-Generation Sequencing (NGS) Is Fastest Growing Technology Segment Owing to Comprehensive Pathogen Detection

Next-generation sequencing (NGS) is the fastest-growing technology segment in the infectious disease molecular diagnostics market, driven by its ability to provide comprehensive and high-throughput pathogen detection. NGS allows for the sequencing of entire genomes, enabling the identification of multiple pathogens simultaneously in a single test. This capability is particularly valuable in cases where infections are caused by unknown or rare pathogens. NGS also allows for the detection of genetic variations in pathogens, such as mutations and resistance genes, which is essential for understanding disease progression and antibiotic resistance.

NGS is increasingly being adopted in research and clinical diagnostics due to its accuracy, speed, and ability to offer more detailed information than traditional diagnostic methods. With the growing demand for personalized medicine and the need for more comprehensive diagnostic approaches, NGS is gaining traction in the molecular diagnostics space. As the cost of sequencing continues to decrease and the technology becomes more widely available, NGS is expected to become a mainstream tool for infectious disease diagnostics, particularly in research settings and in the detection of emerging infectious diseases.

Hospitals and Diagnostic Laboratories Are Largest End-Use Industry Due to High Testing Volume

Hospitals and diagnostic laboratories are the largest end-use industry for infectious disease molecular diagnostics, owing to their critical role in managing the diagnosis and treatment of infections. These healthcare settings conduct a large volume of diagnostic tests on a daily basis, including tests for respiratory infections, bloodstream infections, and STIs. The ability to rapidly and accurately detect infectious agents in these settings is essential for improving patient outcomes and preventing the spread of infections within healthcare facilities.

Molecular diagnostic technologies, particularly PCR and NGS, have become indispensable tools in hospitals and diagnostic laboratories. The adoption of these technologies has enabled healthcare providers to provide faster and more accurate diagnoses, reducing the time to treatment and improving overall patient care. As hospitals and diagnostic laboratories continue to focus on enhancing their diagnostic capabilities, the demand for advanced molecular diagnostics is expected to remain high. Moreover, the increasing number of infectious disease outbreaks and rising healthcare standards worldwide further solidify hospitals and diagnostic laboratories as the largest end-users of molecular diagnostic technologies.

North America Is Largest Region Owing to Advanced Healthcare Infrastructure

North America is the largest region in the infectious disease molecular diagnostics market, driven by its advanced healthcare infrastructure, high adoption of innovative diagnostic technologies, and robust healthcare spending. The United States, in particular, has a well-established healthcare system that prioritizes the use of cutting-edge diagnostic technologies. Hospitals, diagnostic laboratories, and research institutions in North America are at the forefront of adopting molecular diagnostic solutions, including PCR, NGS, and isothermal amplification, to detect and manage infectious diseases.

The region's dominance is also attributed to high healthcare expenditure, government initiatives focused on improving disease surveillance, and strong public health programs aimed at controlling infectious diseases. North America continues to lead the market with a large number of diagnostic manufacturers and a high level of innovation in the molecular diagnostics space. The region's favorable regulatory environment and well-established healthcare infrastructure are expected to sustain its position as the largest market for infectious disease molecular diagnostics.

Leading Companies and Competitive Landscape

The infectious disease molecular diagnostics market is highly competitive, with several global players leading the way in the development, manufacturing, and distribution of molecular diagnostic products. Key players in the market include Abbott Laboratories, Roche Diagnostics, Thermo Fisher Scientific, Siemens Healthineers, BD (Becton, Dickinson and Company), and Cepheid, among others. These companies are focused on expanding their product portfolios to include a wide range of diagnostic solutions, from PCR-based assays to next-generation sequencing platforms.

The competitive landscape is characterized by continuous innovation, strategic partnerships, and acquisitions, as companies seek to expand their market presence and enhance their technological capabilities. Additionally, there is a strong emphasis on improving the accuracy, speed, and accessibility of molecular diagnostic solutions. With the growing demand for more comprehensive and precise diagnostic tools, these leading companies are expected to play a key role in shaping the future of the infectious disease molecular diagnostics market, particularly as new technologies emerge and the demand for faster, more accurate testing continues to rise.

Recent Developments:

• Thermo Fisher Scientific launched a new molecular diagnostic platform for detecting respiratory infections, improving diagnostic speed and accuracy.
• Cepheid received FDA clearance for a rapid PCR test to detect bloodstream infections in less than one hour.
• Roche Diagnostics expanded its molecular diagnostics portfolio with a new Next-Generation Sequencing product for detecting infectious diseases, including HIV and Hepatitis.
• BioMérieux introduced an advanced PCR-based diagnostic tool for detecting gastrointestinal pathogens, offering results in under two hours.
• Abbott Laboratories unveiled a new point-of-care PCR device for real-time detection of respiratory infections, improving diagnostic access in emergency situations.

List of Leading Companies:

• Roche Diagnostics
• Abbott Laboratories
• Thermo Fisher Scientific
• Siemens Healthineers
• Danaher Corporation
• BioMérieux SA
• Becton, Dickinson and Company
• Hologic, Inc.
• QIAGEN N.V.
• Cepheid
• Grifols, S.A.
• Illumina, Inc.
• PerkinElmer, Inc.
• GE Healthcare
• Baxter International Inc.

Report Scope: